Curebound

Accelerating Cancer Cures

aka Padres Pedal the Cause | San Diego, CA | www.curebound.org

GuideStar Charity Check

Curebound

EIN: 46-0552414

Contributions tax deductible
as of November 2023

IRS BMF 509(a)(1)
as of November 13, 2023

View summary

Charity Check report

Mission

To mobilize San Diego to accelerate cancer cures in our lifetime.

Ruling year info

2014

CEO

Anne Marbarger

Main address

9191 Towne Centre Dr. Suite 310

San Diego, CA 92121 USA

Show more contact info

EIN

46-0552414

Subject area info

Philanthropy

Health care quality

Cancers

Cycling

Population served info

Children and youth

Adults

Caregivers

Chronically ill people

Terminally ill people

NTEE code info

Fund Raising and/or Fund Distribution (T12)

IRS subsection

501(c)(3) Public Charity

IRS filing requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Tax forms

Show Forms 990

Communication

Programs and results

Reports and documents

What we aim to solve

SOURCE: Self-reported by organization

Curebound is a San Diego-based 501c3 philanthropic organization that raises and invests strategic funding in translational cancer research projects aimed at accelerating new discoveries to clinical application. Our mission - mobilize San Diego to accelerate cures for cancer in our lifetime. Our vision - a world without cancer.

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

Discovery Grants

One-time seed grants of up to $250,000 for high-risk/ high-reward, translational research. Ideas are innovative and in the early phases where smaller grants can make a big impact in advancing research. Discovery Grants prioritize research that advances therapeutic development and/or has a high likelihood of leveraging extramural funding. Inter-institutional collaboration is required.

Targeted Grants

Larger gifts of $500,000 that aim to fund projects that are closer to clinical stages. Inaugural Targeted Grants require a clinical researcher to be part of the collaborative team in order to ensure the project is geared toward translational application. Priority is given to applications that have a high likelihood of significantly advancing detection, prevention, therapeutic development, access to patient care and/or clinical trials. Targeted Grants fund continuity of ideas from the investigators’ past research, including research that builds upon previously funded Discovery Grants. Interdisciplinary collaboration is required and inter-institutional collaboration, while not required, is preferred.

Cure Prize

Curebound’s highest award for bold innovation in cancer research. Cure Prizes are awarded to teams who present collaborative and/or interdisciplinary solutions that show near-term promise of clinical breakthrough and represent “game changers” in the prevention, diagnosis, access or treatment of cancer patients. Grant funding of $1,000,000+ is awarded and administered over a period of 2-3 years. The first Cure Prize challenge is to develop an innovation that will improve the standard of care for a typically deadly cancer with patient application in 3-5 years.

Population(s) Served

Adults

Caregivers

Chronically ill people

Terminally ill people

Children and youth

Adults

Caregivers

Chronically ill people

Terminally ill people

Children and youth

Adults

Caregivers

Chronically ill people

Terminally ill people

Children and youth

Adults

Caregivers

Chronically ill people

Terminally ill people

Children and youth

Where we work

Awards

Small Nonprofit of the Year 2022

San Diego Business Journal

External reviews

Photos

Videos

Goals & Strategy

SOURCE: Self-reported by organization

Learn about the organization's key goals, strategies, capabilities, and progress.

Charting impact

Four powerful questions that require reflection about what really matters - results.

What is the organization aiming to accomplish?

Curebound unites San Diego’s top research institutions in a collaborative effort to accelerate cancer research into cures. Founded upon a deeply held belief that cures are possible, we believe – and we are seeing – that the next decade will be critical to the development of sophisticated, individualized cancer treatment and the largest opportunity ever seen to advance the way we treat, and ultimately cure cancer. All of this is possible in San Diego.

San Diego is recognized as one of the largest and fastest growing life-science communities in the country and is uniquely positioned as a global center for cancer research, innovation and care. The city is home to three NCI-designated cancer centers, internationally recognized biotech research institutions, top clinical care hospitals and nearly 1,000 life-science companies that are taking cancer discoveries to clinical and commercial stages. Headquartered amongst this powerful scientific hub, Curebound is the catalyst to bring these resources together to drive this work faster and further- to expedite discovery and improve the lives of patients today.

What are the organization's key strategies for making this happen?

Collaboration is at the center of Curebound’s unique grantmaking platform. All Curebound grants demand collaboration among specialized teams from our research partner institutions, enabling the brightest minds from different scientific disciplines to work together to produce better options and outcomes for patients. Curebound research partners include:

- Moores Cancer Center at UC San Diego Health
- Salk Institute
- Sanford-Burnham Prebys
- Rady Children’s Hospital
- La Jolla Institute for Immunology
- Scripps Research

Curebound funds promising, innovative oncology research for all types of cancer, adult and pediatric, in alignment with five scientific investment pillars:

- Prevention and diagnostic tools
- Novel approaches and new therapeutic platforms
- Immunotherapies and personalized vaccines
- Cancer equities
- Pediatric cancers

What are the organization's capabilities for doing this?

What have they accomplished so far and what's next?

In 2021 two highly respected local cancer organizations, the Immunotherapy Foundation and Padres Pedal the Cause, united to form Curebound with an initial goal to raise and invest $100+ million into collaborative cancer research in San Diego. Over the last decade, these two organizations have collectively awarded over $23 million in funding for 90+ research grants that explore 20+ types of adult and pediatric cancers, including 6 pioneering clinical trials and major funding to initiate an Advanced Cell Therapy Lab and the San Diego Center for Precision Immunotherapy.

How we listen

SOURCE: Self-reported by organization

Seeking feedback from people served makes programs more responsive and effective. Here’s how this organization is listening.

We shared information about our current feedback practices.

How is your organization using feedback from the people you serve?

To identify and remedy poor client service experiences, To identify bright spots and enhance positive service experiences, To strengthen relationships with the people we serve, To understand people's needs and how we can help them achieve their goals
Which of the following feedback practices does your organization routinely carry out?

We aim to collect feedback from as many people we serve as possible, We take steps to ensure people feel comfortable being honest with us, We look for patterns in feedback based on people’s interactions with us (e.g., site, frequency of service, etc.), We engage the people who provide feedback in looking for ways we can improve in response, We act on the feedback we receive
What challenges does the organization face when collecting feedback?

It is difficult to get the people we serve to respond to requests for feedback

Financials

Curebound

Fiscal year: Jan 01 - Dec 31

Financial documents

Yes, financials were audited by an independent accountant.

Revenue vs. expenses: breakdown

SOURCE: IRS Form 990

NET GAIN/LOSS: in

Note: When component data are not available, the graph displays the total Revenue and/or Expense values.

Liquidity in 2022

SOURCE: IRS Form 990

3.13

Average of 1.54 over 10 years

Months of cash in 2022

SOURCE: IRS Form 990

20.1

Average of 7.6 over 10 years

Fringe rate in 2022

SOURCE: IRS Form 990

0%

Average of 10% over 10 years

Funding sources

Source: IRS Form 990

Assets & liabilities

Source: IRS Form 990

Financial data

SOURCE: IRS Form 990

Digitizing IRS form 990 data

Curebound

Revenue & expenses

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990 info

Fiscal year ending: Download Data

Revenue
Contributions	$2,352,836
Government Grants	$0
Program Services	$46,447
Investments	$1
Special Events	($25,604)
Sales	$0
Other	$0
Total Revenue	$2,373,680

Expenses
Program Services	$441,640
Administration	$187,287
Fundraising	$1,143,770
Total Expenses	$1,772,697
Net Gain/Loss	$600,983

Functional expenses
Accounting Fees	$22,577
Advertising & Promotion	$268,119
Information Technology Expenses	$42,502
Insurance Expenses	$7,846
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$24,318
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$1,928,086
Government Grants	$0
Program Services	$53,964
Investments	$118
Special Events	($24,701)
Sales	$0
Other	$0
Total Revenue	$1,957,467

Expenses
Program Services	$1,033,936
Administration	$199,586
Fundraising	$1,180,215
Total Expenses	$2,413,737
Net Gain/Loss	($456,270)

Functional expenses
Accounting Fees	$19,977
Advertising & Promotion	$161,443
Information Technology Expenses	$38,323
Insurance Expenses	$10,298
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$1,119
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$2,781,681
Government Grants	$0
Program Services	$64,570
Investments	$260
Special Events	($52,506)
Sales	$0
Other	$0
Total Revenue	$2,794,005

Expenses
Program Services	$1,425,869
Administration	$239,731
Fundraising	$1,062,421
Total Expenses	$2,728,021
Net Gain/Loss	$65,984

Functional expenses
Accounting Fees	$9,917
Advertising & Promotion	$2,776
Information Technology Expenses	$29,984
Insurance Expenses	$12,432
Interest Expenses	$1,529
Investment Management Fees	$0
Legal Fees	$365
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$3,092,560
Government Grants	$0
Program Services	$150,770
Investments	$377
Special Events	($55,501)
Sales	$0
Other	$0
Total Revenue	$3,188,206

Expenses
Program Services	$2,126,971
Administration	$318,924
Fundraising	$830,329
Total Expenses	$3,276,224
Net Gain/Loss	($88,018)

Functional expenses
Accounting Fees	$27,197
Advertising & Promotion	$10,928
Information Technology Expenses	$29,759
Insurance Expenses	$12,053
Interest Expenses	$2,518
Investment Management Fees	$0
Legal Fees	$380
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$3,576,806
Government Grants	$0
Program Services	$190,682
Investments	$435
Special Events	($88,169)
Sales	$0
Other	$0
Total Revenue	$3,679,754

Expenses
Program Services	$2,622,417
Administration	$190,264
Fundraising	$892,118
Total Expenses	$3,704,799
Net Gain/Loss	($25,045)

Functional expenses
Accounting Fees	$11,883
Advertising & Promotion	$51,202
Information Technology Expenses	$26,320
Insurance Expenses	$20,545
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$190
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$4,241,560
Government Grants	$0
Program Services	$237,307
Investments	$277
Special Events	($73,195)
Sales	$15,924
Other	$0
Total Revenue	$4,421,873

Expenses
Program Services	$3,225,911
Administration	$204,469
Fundraising	$940,343
Total Expenses	$4,370,723
Net Gain/Loss	$51,150

Functional expenses
Accounting Fees	$11,185
Advertising & Promotion	$92,555
Information Technology Expenses	$27,588
Insurance Expenses	$20,571
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$452
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$4,339,549
Government Grants	$0
Program Services	$281,605
Investments	$101
Special Events	($77,028)
Sales	$12,767
Other	$0
Total Revenue	$4,556,994

Expenses
Program Services	$3,403,693
Administration	$236,345
Fundraising	$985,546
Total Expenses	$4,625,584
Net Gain/Loss	($68,590)

Functional expenses
Accounting Fees	$13,670
Advertising & Promotion	$71,309
Information Technology Expenses	$26,248
Insurance Expenses	$21,288
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$1,235
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$1,362,861
Government Grants	$0
Program Services	$0
Investments	$52
Special Events	$0
Sales	$0
Other	$0
Total Revenue	$1,362,913

Expenses
Program Services	$236,830
Administration	$193,431
Fundraising	$441,805
Total Expenses	$872,066
Net Gain/Loss	$490,847

Functional expenses
Accounting Fees	$13,774
Advertising & Promotion	$9,323
Information Technology Expenses	$64,909
Insurance Expenses	$12,138
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$421
Pension Plan Contributions	$8,189
Professional Fundraising Expenses	$0

Revenue
Contributions	$18,221,209
Government Grants	$0
Program Services	$2,931,116
Investments	$48
Special Events	($1,347,960)
Sales	$0
Other	$0
Total Revenue	$19,804,413

Expenses
Program Services	$4,643,589
Administration	$369,333
Fundraising	$1,216,147
Total Expenses	$6,229,069
Net Gain/Loss	$13,575,344

Functional expenses
Accounting Fees	$81,957
Advertising & Promotion	$150,712
Information Technology Expenses	$61,704
Insurance Expenses	$25,898
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$28,864
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Curebound

Balance sheet

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990 info

The balance sheet gives a snapshot of the financial health of an organization at a particular point in time. An organization's total assets should generally exceed its total liabilities, or it cannot survive long, but the types of assets and liabilities must also be considered. For instance, an organization's current assets (cash, receivables, securities, etc.) should be sufficient to cover its current liabilities (payables, deferred revenue, current year loan, and note payments). Otherwise, the organization may face solvency problems. On the other hand, an organization whose cash and equivalents greatly exceed its current liabilities might not be putting its money to best use.

Fiscal year ending: Download Data

Assets	Jan 01, 2013	Dec 31, 2013	Change
Contributions	$2,352,836
Cash & Equivalents	$50,177	$282,030	$231,853
Accounts Receivable	$0	$0	$0
Pledges & Grants Receivable	$0	$655,000	$655,000
Receivable, Other	$0	$0	$0
Inventories for Sale or Use	$0	$0	$0
Investment, Securities	$0	$0	$0
Investment, Other	$0	$0	$0
Fixed Assets (LBE - Depreciation)	$0	$9,778	$9,778
Other	$4,791	$174,049	$169,258
Total Assets	$54,968	$1,120,857	$1,065,889

Liabilities	Jan 01, 2013	Dec 31, 2013	Change
Accounts Payable	$0	$464,906	$464,906
Grants Payable	$0	$0	$0
Deferred Revenue	$0	$0	$0
Loans and Notes	$0	$0	$0
Tax-Exempt Bond Liabilities	$0	$0	$0
Other	$0	$0	$0
Total Liabilities	$0	$464,906	$464,906

Fund balance	Jan 01, 2013	Dec 31, 2013	Change
Temporarily Restricted Net Assets	$0	$0	$0
Permanently Restricted Net Assets	$0	$0	$0
Total Restricted Net Assets	$0	$0	$0
Unrestricted Net Assets	$54,968	$655,951	$600,983
Net Assets	$54,968	$655,951	$600,983

Assets	Jan 01, 2014	Dec 31, 2014	Change
Contributions	$1,928,086
Cash & Equivalents	$282,030	$933,430	$651,400
Accounts Receivable	$0	$18,065	$18,065
Pledges & Grants Receivable	$655,000	$260,000	($395,000)
Receivable, Other	$0	$0	$0
Inventories for Sale or Use	$0	$0	$0
Investment, Securities	$0	$0	$0
Investment, Other	$0	$0	$0
Fixed Assets (LBE - Depreciation)	$9,778	$5,574	($4,204)
Other	$174,049	$32,612	($141,437)
Total Assets	$1,120,857	$1,249,681	$128,824

Liabilities	Jan 01, 2014	Dec 31, 2014	Change
Accounts Payable	$464,906	$1,050,000	$585,094
Grants Payable	$0	$0	$0
Deferred Revenue	$0	$0	$0
Loans and Notes	$0	$0	$0
Tax-Exempt Bond Liabilities	$0	$0	$0
Other	$0	$0	$0
Total Liabilities	$464,906	$1,050,000	$585,094

Fund balance	Jan 01, 2014	Dec 31, 2014	Change
Temporarily Restricted Net Assets	$0	$260,000	$260,000
Permanently Restricted Net Assets	$0	$0	$0
Total Restricted Net Assets	$0	$260,000	$260,000
Unrestricted Net Assets	$655,951	($60,319)	($716,270)
Net Assets	$655,951	$199,681	($456,270)

Assets	Jan 01, 2015	Dec 31, 2015	Change
Contributions	$2,781,681
Cash & Equivalents	$933,430	$1,517,757	$584,327
Accounts Receivable	$18,065	$0	($18,065)
Pledges & Grants Receivable	$260,000	$160,038	($99,962)
Receivable, Other	$0	$0	$0
Inventories for Sale or Use	$0	$0	$0
Investment, Securities	$0	$0	$0
Investment, Other	$0	$0	$0
Fixed Assets (LBE - Depreciation)	$5,574	$6,286	$712
Other	$32,612	$20,739	($11,873)
Total Assets	$1,249,681	$1,704,820	$455,139

Liabilities	Jan 01, 2015	Dec 31, 2015	Change
Accounts Payable	$1,050,000	$1,308,675	$258,675
Grants Payable	$0	$0	$0
Deferred Revenue	$0	$0	$0
Loans and Notes	$0	$0	$0
Tax-Exempt Bond Liabilities	$0	$0	$0
Other	$0	$0	$0
Total Liabilities	$1,050,000	$1,308,675	$258,675

Fund balance	Jan 01, 2015	Dec 31, 2015	Change
Temporarily Restricted Net Assets	$260,000	$0	-$260,000
Permanently Restricted Net Assets	$0	$0	$0
Total Restricted Net Assets	$260,000	$0	($260,000)
Unrestricted Net Assets	($60,319)	$396,145	$456,464
Net Assets	$199,681	$396,145	$196,464

Assets	Jan 01, 2016	Dec 31, 2016	Change
Contributions	$3,092,560
Cash & Equivalents	$1,517,757	$2,168,974	$651,217
Accounts Receivable	$0	$0	$0
Pledges & Grants Receivable	$160,038	$262,064	$102,026
Receivable, Other	$0	$0	$0
Inventories for Sale or Use	$0	$0	$0
Investment, Securities	$0	$0	$0
Investment, Other	$0	$0	$0
Fixed Assets (LBE - Depreciation)	$6,286	$0	($6,286)
Other	$20,739	$17,112	($3,627)
Total Assets	$1,704,820	$2,448,150	$743,330

Liabilities	Jan 01, 2016	Dec 31, 2016	Change
Accounts Payable	$1,308,675	$2,140,023	$831,348
Grants Payable	$0	$0	$0
Deferred Revenue	$0	$0	$0
Loans and Notes	$0	$0	$0
Tax-Exempt Bond Liabilities	$0	$0	$0
Other	$0	$0	$0
Total Liabilities	$1,308,675	$2,140,023	$831,348

Fund balance	Jan 01, 2016	Dec 31, 2016	Change
Temporarily Restricted Net Assets	$0	$0	$0
Permanently Restricted Net Assets	$0	$0	$0
Total Restricted Net Assets	$0	$0	$0
Unrestricted Net Assets	$396,145	$308,127	($88,018)
Net Assets	$396,145	$308,127	($88,018)

Assets	Jan 01, 2017	Dec 31, 2017	Change
Contributions	$3,576,806
Cash & Equivalents	$2,168,974	$2,566,468	$397,494
Accounts Receivable	$0	$0	$0
Pledges & Grants Receivable	$262,064	$181,160	($80,904)
Receivable, Other	$0	$0	$0
Inventories for Sale or Use	$0	$0	$0
Investment, Securities	$0	$0	$0
Investment, Other	$0	$0	$0
Fixed Assets (LBE - Depreciation)	$0	$0	$0
Other	$17,112	$57,532	$40,420
Total Assets	$2,448,150	$2,805,160	$357,010

Liabilities	Jan 01, 2017	Dec 31, 2017	Change
Accounts Payable	$2,140,023	$2,522,078	$382,055
Grants Payable	$0	$0	$0
Deferred Revenue	$0	$0	$0
Loans and Notes	$0	$0	$0
Tax-Exempt Bond Liabilities	$0	$0	$0
Other	$0	$0	$0
Total Liabilities	$2,140,023	$2,522,078	$382,055

Fund balance	Jan 01, 2017	Dec 31, 2017	Change
Temporarily Restricted Net Assets	$0	$9,550	$9,550
Permanently Restricted Net Assets	$0	$0	$0
Total Restricted Net Assets	$0	$9,550	$9,550
Unrestricted Net Assets	$308,127	$273,532	($34,595)
Net Assets	$308,127	$283,082	($25,045)

Assets	Jan 01, 2018	Dec 31, 2018	Change
Contributions	$4,241,560
Cash & Equivalents	$2,566,468	$3,151,021	$584,553
Accounts Receivable	$0	$0	$0
Pledges & Grants Receivable	$181,160	$144,219	($36,941)
Receivable, Other	$0	$0	$0
Inventories for Sale or Use	$0	$0	$0
Investment, Securities	$0	$0	$0
Investment, Other	$0	$0	$0
Fixed Assets (LBE - Depreciation)	$0	$0	$0
Other	$57,532	$68,756	$11,224
Total Assets	$2,805,160	$3,363,996	$558,836

Liabilities	Jan 01, 2018	Dec 31, 2018	Change
Accounts Payable	$2,522,078	$3,029,764	$507,686
Grants Payable	$0	$0	$0
Deferred Revenue	$0	$0	$0
Loans and Notes	$0	$0	$0
Tax-Exempt Bond Liabilities	$0	$0	$0
Other	$0	$0	$0
Total Liabilities	$2,522,078	$3,029,764	$507,686

Fund balance	Jan 01, 2018	Dec 31, 2018	Change
Temporarily Restricted Net Assets	$9,550	$0	-$9,550
Permanently Restricted Net Assets	$0	$0	$0
Total Restricted Net Assets	$9,550	$0	($9,550)
Unrestricted Net Assets	$273,532	$334,232	$60,700
Net Assets	$283,082	$334,232	$51,150

Assets	Jan 01, 2019	Dec 31, 2019	Change
Contributions	$4,339,549
Cash & Equivalents	$3,151,021	$3,254,098	$103,077
Accounts Receivable	$0	$0	$0
Pledges & Grants Receivable	$144,219	$142,230	($1,989)
Receivable, Other	$0	$0	$0
Inventories for Sale or Use	$0	$0	$0
Investment, Securities	$0	$0	$0
Investment, Other	$0	$0	$0
Fixed Assets (LBE - Depreciation)	$0	$0	$0
Other	$68,756	$76,966	$8,210
Total Assets	$3,363,996	$3,473,294	$109,298

Liabilities	Jan 01, 2019	Dec 31, 2019	Change
Accounts Payable	$3,029,764	$3,207,652	$177,888
Grants Payable	$0	$0	$0
Deferred Revenue	$0	$0	$0
Loans and Notes	$0	$0	$0
Tax-Exempt Bond Liabilities	$0	$0	$0
Other	$0	$0	$0
Total Liabilities	$3,029,764	$3,207,652	$177,888

Fund balance	Jan 01, 2019	Dec 31, 2019	Change
Temporarily Restricted Net Assets	N/A	N/A	N/A
Permanently Restricted Net Assets	N/A	N/A	N/A
Total Restricted Net Assets	$0	$0	$0
Unrestricted Net Assets	$334,232	$265,642	($68,590)
Net Assets	$334,232	$265,642	($68,590)

Assets	Jan 01, 2020	Dec 31, 2020	Change
Contributions	$1,362,861
Cash & Equivalents	$3,254,098	$682,767	($2,571,331)
Accounts Receivable	$0	$0	$0
Pledges & Grants Receivable	$142,230	$135,490	($6,740)
Receivable, Other	$0	$0	$0
Inventories for Sale or Use	$0	$0	$0
Investment, Securities	$0	$0	$0
Investment, Other	$0	$0	$0
Fixed Assets (LBE - Depreciation)	$0	$0	$0
Other	$76,966	$61,788	($15,178)
Total Assets	$3,473,294	$880,045	($2,593,249)

Liabilities	Jan 01, 2020	Dec 31, 2020	Change
Accounts Payable	$3,207,652	$46,561	($3,161,091)
Grants Payable	$0	$0	$0
Deferred Revenue	$0	$0	$0
Loans and Notes	$0	$76,995	$76,995
Tax-Exempt Bond Liabilities	$0	$0	$0
Other	$0	$0	$0
Total Liabilities	$3,207,652	$123,556	($3,084,096)

Curebound

Financial trends analysis Glossary & formula definitions

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990 info

This snapshot of Curebound’s financial trends applies Nonprofit Finance Fund® analysis to data hosted by GuideStar. While it highlights the data that matter most, remember that context is key – numbers only tell part of any story.

Created in partnership with

Fiscal year: Jan 01 - Dec 31 View full report Download data

Business model indicators

Profitability	2017	2018	2019	2020	2022
Unrestricted surplus (deficit) before depreciation	-$19,559	$79,272	-$50,121	$510,179	$6,847,535
As % of expenses	-0.5%	1.8%	-1.1%	59.8%	111.2%
Unrestricted surplus (deficit) after depreciation	-$34,595	$60,700	-$68,590	$490,847	$6,775,799
As % of expenses	-0.9%	1.4%	-1.5%	56.3%	108.8%

Revenue composition
Total revenue (unrestricted & restricted)	$3,679,754	$4,421,873	$4,556,994	$1,362,913	$19,804,413
Total revenue, % change over prior year	15.4%	20.2%	3.1%	-70.1%	0.0%
Program services revenue	5.2%	5.4%	6.2%	0.0%	14.8%
Membership dues	0.0%	0.0%	0.0%	0.0%	0.0%
Investment income	0.0%	0.0%	0.0%	0.0%	0.0%
Government grants	0.0%	0.0%	0.0%	0.0%	0.0%
All other grants and contributions	94.8%	94.3%	93.5%	100.0%	85.2%
Other revenue	0.0%	0.4%	0.3%	0.0%	0.0%

Expense composition
Total expenses before depreciation	$3,689,763	$4,352,151	$4,607,115	$852,734	$6,157,333
Total expenses, % change over prior year	13.0%	18.0%	5.9%	-81.5%	0.0%
Personnel	14.2%	12.7%	12.1%	55.8%	18.7%
Professional fees	0.7%	1.9%	1.7%	10.1%	17.4%
Occupancy	1.2%	1.3%	1.4%	7.4%	0.1%
Interest	0.0%	0.0%	0.0%	0.0%	0.0%
Pass-through	65.1%	67.6%	67.9%	0.0%	48.7%
All other expenses	18.7%	16.5%	16.9%	26.7%	15.1%

Full cost components (estimated)	2017	2018	2019	2020	2022
Total expenses (after depreciation)	$3,704,799	$4,370,723	$4,625,584	$872,066	$6,229,069
One month of savings	$307,480	$362,679	$383,926	$71,061	$513,111
Debt principal payment	$0	$0	$0	$0	$0
Fixed asset additions	$0	$0	$0	$0	$0
Total full costs (estimated)	$4,012,279	$4,733,402	$5,009,510	$943,127	$6,742,180

Capital structure indicators

Liquidity	2017	2018	2019	2020	2022
Months of cash	8.3	8.7	8.5	9.6	20.1
Months of cash and investments	8.3	8.7	8.5	9.6	20.1
Months of estimated liquid unrestricted net assets	0.9	0.9	0.7	10.6	13.8

Balance sheet composition	2017	2018	2019	2020	2022
Cash	$2,566,468	$3,151,021	$3,254,098	$682,767	$10,319,720
Investments	$0	$0	$0	$0	$0
Receivables	$181,160	$144,219	$142,230	$135,490	$13,044,813
Gross land, buildings, equipment (LBE)	$0	$0	$0	$0	$0
Accumulated depreciation (as a % of LBE)	0.0%	0.0%	0.0%	0.0%	0.0%
Liabilities (as a % of assets)	89.9%	90.1%	92.4%	14.0%	14.0%
Unrestricted net assets	$273,532	$334,232	$265,642	$756,489	$7,082,323
Temporarily restricted net assets	$9,550	$0	N/A	N/A	N/A
Permanently restricted net assets	$0	$0	N/A	N/A	N/A
Total restricted net assets	$9,550	$0	$0	$0	$13,201,698
Total net assets	$283,082	$334,232	$265,642	$756,489	$20,284,021

Key data checks

Key data checks	2017	2018	2019	2020	2022
Material data errors	No	No	No	No	No

Operations

The people, governance practices, and partners that make the organization tick.

Documents

Letter of Determination

Form 1023/1024 is not available for this organization

CEO

Anne Marbarger

LinkedIn profile

Anne Marchand is the CEO of Curebound. With her eyes set on significantly growing the organization, Anne is responsible for building a community of sponsors, riders, fundraisers and passionate cancer warriors in support of the organization's mission to fund the best collaborative cancer research in San Diego. Anne began working with Pedal the Cause in 2015 as Director of Programs and was promoted to lead the organization the following year.

Number of employees

Source: IRS Form 990

Curebound

Officers, directors, trustees, and key employees

SOURCE: IRS Form 990

Compensation

Other

Show data for fiscal year

Compensation data

Download up to 5 most recent years of officer and director compensation data for this organization

There are no highest paid employees recorded for this organization.

Curebound

Board of directors
as of 09/01/2023

SOURCE: Self-reported by organization

Board of directors data

Download the most recent year of board of directors data for this organization

Board chair

William Koman

Fernanda Whitworth

Larry Bloch

Mark Cafferty

San Diego Regional Economic Development Co

Aaron Davis

Boxer Capital

Rich Heyman

ARCH Venture Partners

John Hood

Endeavor Biomedicines

Catriona Jamieson

UC San Diego

Donald Kearns

Christian Tresse

Bernstein Private Wealth Management

Cheryl Anderson

Magda Marquet

Rob Singh

CONAM

Daniel Ryan

Alexandria Real Estate Equities

Donald Ankeny

Westcore

Organizational demographics

SOURCE: Self-reported; last updated 8/28/2023

Candid has made improvements to the race and ethnicity options.

Who works and leads organizations that serve our diverse communities? Candid partnered with CHANGE Philanthropy on this demographic section.

Leadership

The organization's leader identifies as:

Race & ethnicity

White/Caucasian/European

Gender identity

Female

Disability status

Person without a disability

Race & ethnicity

No data

Gender identity

Sexual orientation

No data

Disability

No data

Equity strategies

Last updated: 09/01/2023

GuideStar partnered with Equity in the Center - an organization that works to shift mindsets, practices, and systems to increase racial equity - to create this section. Learn more

Data

We analyze disaggregated data and root causes of race disparities that impact the organization's programs, portfolios, and the populations served.
We disaggregate data to adjust programming goals to keep pace with changing needs of the communities we support.

Policies and processes

We use a vetting process to identify vendors and partners that share our commitment to race equity.
We help senior leadership understand how to be inclusive leaders with learning approaches that emphasize reflection, iteration, and adaptability.
We engage everyone, from the board to staff levels of the organization, in race equity work and ensure that individuals understand their roles in creating culture such that one’s race identity has no influence on how they fare within the organization.

Curebound

Accelerating Cancer Cures

Mission

Is this your nonprofit?

Programs and results

Reports and documents

What we aim to solve

Our programs

Discovery Grants

Targeted Grants

Cure Prize

Where we work

Awards

Goals & Strategy

Charting impact

What is the organization aiming to accomplish?

What are the organization's key strategies for making this happen?

What are the organization's capabilities for doing this?

What have they accomplished so far and what's next?

How we listen

Financials

Financial documents

Revenue vs. expenses: breakdown

Liquidity in 2022 info

3.13

Months of cash in 2022 info

20.1

Fringe rate in 2022 info

0%

Funding sources info

Assets & liabilities info

Financial data

Digitizing IRS form 990 data

Curebound

Curebound

Curebound

Business model indicators

Capital structure indicators

Key data checks

Operations

Documents

CEO

Anne Marbarger

Number of employees

Curebound

Compensation data

Curebound

Board of directors data

William Koman

Organizational demographics

Leadership

Race & ethnicity

Gender identity

Sexual orientation

Disability

Equity strategies

Liquidity in 2022

Months of cash in 2022

Fringe rate in 2022

Funding sources

Assets & liabilities